Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Akorn, Inc.
Akorn-Strides, LLC Announces FDA Approval for Rifampin for Injection USP, 600 mg/Vial
June 13th, 2008
Akorn-Strides, LLC announced the approval of an ANDA for Rifampin for Injection USP, 600 mg/vial. This is the first lyophilized Injectable product approval for the Joint Venture. Akorn-Strides, LLC is a Joint Venture that was formed in 2005 by Akorn, Inc. (NASDAQ: AKRX) and Strides Arcolab Limited (NSE: STAR) (BSE: 532531). The primary mission for the Joint Venture is to develop liquid, lyophilized and dry powder formulations of generic injectable products targeting several therapeutic markets with a major focus on anti-infectives, analgesics and CNS medicines. Rifampin for Injection is a semi synthetic antibiotic indicated for the treatment of both...
Source: Health Business Week (2008-06-13)
|
